CLINICAL TRIALS PROFILE FOR ORASONE

505(b)(2) Clinical Trials for ORASONE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT03742258 ↗	Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2019-03-13	The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL). ?Investigational? means that TAK-659 has not been approved by the United States Food and Drug Administration (FDA) for use as a prescription or over-the-counter medication to treat a certain condition. The primary purpose of this study is to find the appropriate and safe dose of the study drug to be used in combination with standard chemotherapy for the treatment of your disease and to determine how well the drug works in treating the disease. Other objectives include measuring the amount of the study drug in the body at different times after taking the study drug. Participation in the study is expected to last for up to 3 years after receiving the last dose of the study drug. Patients will receive the study treatment for up to 18 weeks, as long as they are benefitting.
OTC	NCT03742258 ↗	Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma	Active, not recruiting	Northwestern University	Phase 1	2019-03-13	The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL). ?Investigational? means that TAK-659 has not been approved by the United States Food and Drug Administration (FDA) for use as a prescription or over-the-counter medication to treat a certain condition. The primary purpose of this study is to find the appropriate and safe dose of the study drug to be used in combination with standard chemotherapy for the treatment of your disease and to determine how well the drug works in treating the disease. Other objectives include measuring the amount of the study drug in the body at different times after taking the study drug. Participation in the study is expected to last for up to 3 years after receiving the last dose of the study drug. Patients will receive the study treatment for up to 18 weeks, as long as they are benefitting.

All Clinical Trials for ORASONE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003389 ↗	Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	1999-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining more than one drug with radiation therapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is most effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work, with or without radiation therapy, in treating patients with Hodgkin's lymphoma.
NCT00003389 ↗	Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma	Completed	Eastern Cooperative Oncology Group	Phase 3	1999-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining more than one drug with radiation therapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is most effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work, with or without radiation therapy, in treating patients with Hodgkin's lymphoma.
NCT00004228 ↗	Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	2000-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
NCT00004228 ↗	Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma	Completed	Children's Oncology Group	Phase 3	2000-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.

Clinical Trial Conditions for ORASONE

Condition Name

Condition Name for ORASONE
Intervention	Trials
Acute Lymphoblastic Leukemia	14
Diffuse Large B-Cell Lymphoma	9
Untreated Adult Acute Lymphoblastic Leukemia	9
Leukemia	9

Condition MeSH

Condition MeSH for ORASONE
Intervention	Trials
Lymphoma	44
Leukemia	33
Precursor Cell Lymphoblastic Leukemia-Lymphoma	33
Leukemia, Lymphoid	32

Clinical Trial Locations for ORASONE

Trials by Country

Trials by Country for ORASONE
Location	Trials
Canada	98
Australia	36
New Zealand	14
Puerto Rico	8
Switzerland	5

Trials by US State

Trials by US State for ORASONE
Location	Trials
Texas	55
California	45
Illinois	42
Washington	40
New York	39

Clinical Trial Progress for ORASONE

Clinical Trial Phase

Clinical Trial Phase for ORASONE
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	21
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for ORASONE
Clinical Trial Phase	Trials
Recruiting	36
Active, not recruiting	27
Completed	22

Clinical Trial Sponsors for ORASONE

Sponsor Name

Sponsor Name for ORASONE
Sponsor	Trials
National Cancer Institute (NCI)	83
M.D. Anderson Cancer Center	24
Children's Oncology Group	9

Sponsor Type

Sponsor Type for ORASONE
Sponsor	Trials
Other	105
NIH	86
Industry	45

Last updated: April 28, 2026

Orasone: What do clinical-trials, market signals, and pricing dynamics say about the path to sales?

What is Orasone and what is known publicly about its clinical development?

No sufficient, source-citable information is available in the provided material to identify:

• Orasone’s active pharmaceutical ingredient(s), formulation, route, and country of commercialization
• Its trial sponsor, study identifiers (e.g., NCT numbers), phases, endpoints, and enrollment status
• Its latest clinical readouts (with dates) and planned next milestones

Because the request requires a “clinical trials update” and “market analysis and projection,” and because no verifiable trial- and market-specific facts are present, a complete and accurate assessment cannot be produced.

---

Is Orasone in the clinic now, and what is the latest status update?

No source-citable trial data is provided to support:

• Phase (I/II/III) placement
• Recruitment status (not yet recruiting, recruiting, active, completed)
• Reported efficacy/safety outcomes
• Interim or final results timing

A clinical-trials update would require explicit trial identifiers and dated outcomes. Without those, the update would not meet an accuracy standard suitable for R&D or investment decision-making.

---

What does the market data say, and how should sales be projected?

No source-citable market inputs are present to support projection modeling, such as:

• Indication and target patient population definition
• Target geography and formulary access status
• Competitive landscape (mechanism class, marketed comparators, pipeline rivals)
• Pricing benchmarks and payer dynamics
• Channel and volume assumptions

A market analysis and sales projection cannot be computed or justified without those data points.

---

What are the key commercial and IP checkpoints that could drive upside or constrain adoption?

No Orasone-specific IP terms, patent expiry windows, exclusivity, or regulatory milestones are provided. Without:

• patent family structure (primary/secondary patents),
• jurisdictions of protection,
• regulatory exclusivities (data/market),
• and key regulatory milestones (MMA/MAA/BLA filing dates, approval dates),

no actionable IP checkpoint analysis can be produced.

---

Key Takeaways

• A clinical-trials update for Orasone cannot be produced because no source-citable trial facts (design, phase, status, endpoints, dates) are provided.
• A market analysis and sales projection cannot be produced because no indication, patient, pricing, competition, or geography inputs are provided.
• An IP-driven commercial checkpoint analysis cannot be produced because no Orasone patent and regulatory timeline inputs are provided.

---

FAQs

1) What is Orasone’s active ingredient and intended indication?

Cannot be answered from the provided information.

2) What phase is Orasone in and what is the latest trial readout?

Cannot be answered from the provided information.

3) Who are the key competitors and how does Orasone differentiate?

Cannot be answered from the provided information.

4) What pricing and reimbursement path should be modeled for Orasone?

Cannot be answered from the provided information.

5) When does Orasone’s patent protection expire and where?

Cannot be answered from the provided information.

---

References

[1] No sources were provided in the prompt.